EBEric Bernard

Eric Bernard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eric Bernard has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Zika virus reprograms the host tRNA epitranscriptome to adapt translation to A-ending codon bias

    by Patrick Eldin, Eric Bernard, Cathrine B. Vågbø, Lynn George, Masahiko Ajiro, Masatoshi Hagiwara, Geir Slupphaug, Laurence Briant

    The codon usage bias of the Zika virus (ZIKV) genome is skewed towards AA-ending codons, which are preferentially decoded by U34-modified cognate tRNAs. This contrasts with the human host’s preference for AG-ending codons, suggesting that ZIKV may exploit specific tRNA modifications to optimize protein synthesis within human cells. To test this hypothesis, we used codon-biased eGFP sensors and found that ZIKV infection transiently increased the expression of AA-biased GFP at the expense of AG-biased GFP. Mass spectrometry analysis further showed that ZIKV virus infection increases mcm 5 s 2 U 34 tRNA modification content in host cells. In ELP1-deficient cells, which exhibit reduced U 34 modifications, ZIKV replication was impaired. Enhancing U 34 modification through using a small molecule known to restore ELP1 expression, rescued viral replication in these cells. Moreover, CRISPR/Cas9 and shRNA-mediated knockdown of key enzymes involved in U 34 modification, ELP1, ALKBH8, and CTU1, significantly reduced ZIKV replication. Collectively, these results provide strong evidence that ZIKV reprograms the host tRNA epitranscriptome and exploits host cell tRNA modifications, particularly at the wobble position U 34 , to optimize translation of its own proteins and promote viral replication.


  • Open Access

    The DEAD box RNA helicase DDX42 is an intrinsic inhibitor of positive-strand RNA viruses

    by Boris Bonaventure, Antoine Rebendenne, Francisco Garcia de Gracia, Joe McKellar, Ségolène Gracias, Emmanuel Labaronne, Marine Tauziet, Ana Luiza Chaves Valadão, Eric Bernard, Laurence Briant, et al.

    Genome-wide screens are powerful approaches to unravel new regulators of viral infections. Here, we used a CRISPR/Cas9 screen to reveal new HIV-1 inhibitors. This approach led us to identify the RNA helicase DDX42 as an intrinsic antiviral inhibitor. DDX42 was previously described as a non-processive helicase, able to bind RNA secondary structures such as G-quadruplexes, with no clearly defined function ascribed. Our data show that depletion of endogenous DDX42 significantly increased HIV-1 DNA accumulation and infection in cell lines and primary cells. DDX42 overexpression inhibited HIV-1, whereas a dominant-negative mutant increased infection. Importantly, DDX42 also restricted retrotransposition of LINE-1, infection with other retroviruses and positive-strand RNA viruses, including CHIKV and SARS-CoV-2. However, DDX42 did not inhibit infection with three negative-strand RNA viruses, arguing against a general, unspecific effect on target cells, which was confirmed by RNA-seq analysis. DDX42 was found in the vicinity of viral elements by proximity ligation assays, and cross-linking RNA immunoprecipitation confirmed a specific interaction of DDX42 with RNAs from sensitive viruses. This strongly suggested a direct mode of action of DDX42 on viral ribonucleoprotein complexes. Taken together, our results show for the first time a new and important role of DDX42 in intrinsic antiviral immunity.